Prevention of serious skeletal-related events by interventional radiology techniques in patients with malignant paraganglioma and pheochromocytoma
- 182 Downloads
Bone metastases (BM) and skeletal-related events (SRE) are frequent in patients with malignant pheochromocytoma and paraganglioma (PPM) and the best modality of prevention unknown. The role of interventional radiology (IR) techniques for the prevention of SRE in the multidisciplinary management of malignant PPM has not been evaluated in that setting.
Single referral center retrospective review of all patients with malignant PPM with BM from 2000 to 2016. The primary endpoint was the time to first serious SRE (TTSRE). At time of inclusion, patients with high bone tumor burden disease were defined as those having more than five BM with the biggest exceeding 2 cm (Group A) and patients with moderate bone tumor burden disease were defined as those having five or less BM or no BM exceeding 2 cm (Group B).
A total of 28 patients were included in this study. Thirteen were treated by IR techniques for prevention of first serious SRE. After a median follow-up of 48.2 months, the median TTSRE was not reached in patients treated by IR techniques and was 26.0 months in patients without IR procedures (p = .058). When comparing patients in group B, TTSRE was significantly higher in patients treated by IR (10 patients) when compared to patients without IR procedures (12 patients) (p = .021).
IR techniques may help to delay the occurrence of first serious SRE in patients with malignant PPM with moderate bone tumor burden disease. Prospective studies are expected to confirm these results.
KeywordsParaganglioma Pheochromocytoma Bone metastases Interventional radiology Skeletal-related events
Paragangliomas and pheochromocytomas
Time to first serious SRE
Positron emission tomography
Compilance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.H. Chen, R.S. Sippel, M.S. O’Dorisio, A.I. Vinik, R.V. Lloyd, K. Pacak, and North American Neuroendocrine Tumor Society (NANETS), The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39, 775 (2010)CrossRefGoogle Scholar
- 3.G. Eisenhofer, S.R. Bornstein, F.M. Brouwers, N.-K.V. Cheung, P.L. Dahia, R.R. de Krijger, T.J. Giordano, L.A. Greene, D.S. Goldstein, H. Lehnert, W.M. Manger, J.M. Maris, H.P.H. Neumann, K. Pacak, B.L. Shulkin, D.I. Smith, A.S. Tischler, W.F. Young, Malignant pheochromocytoma: current status and initiatives for future progress. Endocr. Relat. Cancer 11, 423 (2004)CrossRefGoogle Scholar
- 4.L. Amar, E. Baudin, N. Burnichon, S. Peyrard, S. Silvera, J. Bertherat, X. Bertagna, M. Schlumberger, X. Jeunemaitre, A.-P. Gimenez-Roqueplo, P.-F. Plouin, Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J. Clin. Endocrinol. Metab. 92, 3822 (2007)CrossRefGoogle Scholar
- 6.H.J.L.M. Timmers, C.C. Chen, J.A. Carrasquillo, M. Whatley, A. Ling, G. Eisenhofer, K.S. King, J.U. Rao, R.A. Wesley, K.T. Adams, K. Pacak, Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J. Natl. Cancer Inst. 104, 700 (2012)CrossRefGoogle Scholar
- 7.S. Hescot, S. Leboulleux, L. Amar, D. Vezzosi, I. Borget, C. Bournaud-Salinas, C. de la Fouchardiere, R. Libé, C. Do Cao, P. Niccoli, A. Tabarin, I. Raingeard, C. Chougnet, S. Giraud, A.-P. Gimenez-Roqueplo, J. Young, F. Borson-Chazot, J. Bertherat, J.-L. Wemeau, X. Bertagna, P.-F. Plouin, M. Schlumberger, E. Baudin, and French group of Endocrine and Adrenal tumors (Groupe des Tumeurs Endocrines-REseau NAtional des Tumeurs ENdocrines and COrtico-MEdullo Tumeurs Endocrines networks), One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 98, 4006 (2013)CrossRefGoogle Scholar
- 13.U.S. Department of Health and Human Services. National Institutes of Health. (National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) Version 4. 03, 2010), https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 7 Sept 2017
- 20.O. Sartor, R. Coleman, S. Nilsson, D. Heinrich, S.I. Helle, J.M. O’Sullivan, S.D. Fosså, A. Chodacki, P. Wiechno, J. Logue, A. Widmark, D.C. Johannessen, P. Hoskin, N.D. James, A. Solberg, I. Syndikus, N.J. Vogelzang, C.G. O’Bryan-Tear, M. Shan, Ø.S. Bruland, C. Parker, Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 15, 738 (2014).CrossRefGoogle Scholar